Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA ® (canagliflozin) Compared to Other Diabetes Medications
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Invokana | Pharmaceuticals | Study